Roche Holding AG





Market Closed - Swiss Exchange 11:30:28 2024-06-20 am EDT 5-day change 1st Jan Change
250 CHF +0.08% Intraday chart for Roche Holding AG +2.67% +2.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours MT
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating ZD
Swiss Equities Close Higher as SNB Delivers Another Rate Cut MT
Roche: new detection test for lymphoma CF
Roche Launches First Clinically Approved Test for B-cell Lymphoma MT
Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma CI
Roche: collaboration agreement with Ascidian Therapeutics CF
Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal DJ
Roche partners with Ascidian Therapeutics to develop gene therapies RE
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases CI
Roche: approval for digital pathology system CF
ROCHE HOLDINGS AG : Goldman Sachs gives a Sell rating ZD
ROCHE HOLDINGS AG : Deutsche Bank sticks Neutral ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Barclays ZD
ROCHE HOLDINGS AG : JP Morgan gives a Sell rating ZD
Roche: positive phase III data in lymphoma CF
Roche's Blood Cancer Combo Reduces Risk of Death in Late-stage Study MT
Transcript : Roche Holding AG - Shareholder/Analyst Call
Roche?s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma CI
Roche: collaboration agreement in colon cancer CF
Nkarta, Inc. Appoints George Vratsanos as Board of Directors CI
AbbVie inks immune disorder drug licensing deal with China's FutureGen RE
Swiss Stocks Flash Red as US Fed Decision Takes Spotlight MT
Global markets live: ABB, Roche, Microsoft, Apple, Tesla... Our Logo
Roche's Lung Cancer Drug Notches EU Win After 'Unprecedented' Late-stage Study Results MT
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
249.8 CHF
Average target price
278.1 CHF
Spread / Average Target
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche's Investigational Breast Cancer Treatment Granted Breakthrough Designation by US FDA